iScience (Aug 2023)

Methemoglobin as a marker of acute anemic stress in cardiac surgery

  • Nikhil Mistry,
  • Gregory M.T. Hare,
  • Nadine Shehata,
  • Robert S. Kramer,
  • Hosam F. Fawzy,
  • Robert A. Baker,
  • Paula Carmona,
  • Richard Saczkowski,
  • Daniela Filipescu,
  • Christella S. Alphonsus,
  • Antoine Rochon,
  • Alexander J. Gregory,
  • Boris Khanykin,
  • Jonathan D. Leff,
  • Eva Mateo,
  • Dimos Karangelis,
  • Juan C. Tellez,
  • Tarit Saha,
  • Dennis T. Ko,
  • Duminda N. Wijeysundera,
  • Subodh Verma,
  • C. David Mazer

Journal volume & issue
Vol. 26, no. 8
p. 107429

Abstract

Read online

Summary: Biological evidence supports plasma methemoglobin as a biomarker for anemia-induced tissue hypoxia. In this translational planned substudy of the multinational randomized controlled transfusion thresholds in cardiac surgery (TRICS-III) trial, which included adults undergoing cardiac surgery requiring cardiopulmonary bypass with a moderate-to-high risk of death, we investigated the relationship between perioperative hemoglobin concentration (Hb) and methemoglobin; and evaluated its association with postoperative outcomes. The primary endpoint was a composite of death, myocardial infarction, stroke, and severe acute kidney injury at 28 days. We observe weak non-linear associations between decreasing Hb and increasing methemoglobin, which were strongest in magnitude at the post-surgical time point. Increased levels of post-surgical methemoglobin were associated with a trend toward an elevated risk for stroke and exploratory neurological outcomes. Our generalizable study demonstrates post-surgical methemoglobin may be a marker of anemia-induced organ injury/dysfunction, and may have utility for guiding personalized approaches to anemia management. Clinicaltrials.gov registration NCT02042898.

Keywords